Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Neuropharmacology. 2011 Dec 17;62(4):1874–1881. doi: 10.1016/j.neuropharm.2011.12.013

Figure 1.

Figure 1

Sequence and target receptors of PLP-BPI. PLP-BPI is a linear 33-amino acid peptide, which is composed of the antigenic peptide, PLP139–151 and the ICAM-1 binding peptide, LABL, which is derived from the α-subunit of LFA-1 (CD11a237–246). Both peptides are covalently conjugated to each other via a linker composed of ε-aminocaproic acid and glycine. The N- and C- termini of the peptide are capped by acetylation and amidation, respectively. The hypothesis is that the PLP139–151 portion will bind to MHC-II (I-As) and LABL will simultaneously bind to ICAM-1 on the surface of the APC.